TrialAmerican journal of hematology2020

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.

Adrian C Newland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.